Metropolis Healthcare Unveils Centre of Genomics to Drive Precision Medicine in India

Metropolis Healthcare Limited has launched its Centre of Genomics in India, a pioneering initiative designed to strengthen the country’s capabilities in molecular diagnostics and personalized medicine. This move underscores the company’s commitment to innovation in healthcare, particularly in areas such as oncology, prenatal care, and rare disease management.

The Centre of Genomics will serve as a hub for advanced genetic testing, enabling clinicians to provide more accurate diagnoses and tailored treatment plans. By integrating genomics with pathology and companion diagnostics, Metropolis aims to bridge critical gaps in India’s healthcare ecosystem and empower patients with predictive and preventive solutions.

Key Highlights

• Focus Areas: Molecular genomics, superspeciality pathology, and companion diagnostics.
• Innovative Tests: BRCA1/BRCA2 genetic testing for hereditary breast and ovarian cancer; non-invasive prenatal screening (NIPT) for chromosomal abnormalities.
• Clinical Impact: Enhanced early detection of cancers, genetic disorders, and pregnancy related risks.
• Strategic Vision: Strengthening India’s healthcare infrastructure with precision medicine and AI-driven genomics.
• Patient Benefit: Personalized treatment pathways, improved outcomes, and reduced long-term healthcare costs.

This launch positions Metropolis Healthcare at the forefront of India’s genomics revolution, aligning with global trends in predictive and preventive medicine.

Sources: Medgate Today, Healthcare Radius, The Week